The Scientist Logo_white

Improving Cancer Immunotherapy with Anticancer Adenoviruses

A mesenchymal stromal cell-based vector simultaneously delivers multiple viruses, improving CAR T cell activity.




The tumor microenvironment (TME) is a barrier to adoptive cell therapy because it promotes tumor growth and metastasis while suppressing anticancer immune responses. A novel therapy deploys adenoviruses that disrupt and manipulate the TME to create a more immunostimulatory setting. However, delivering the therapy to solid tumors is challenging, as innate or adaptive immune responses often eliminate viruses before they reach the tumor site.

Download this research summary from IsoPlexis to find out how researchers delivered anticancer adenoviruses to tumor sites with the help of a mesenchymal stromal cell-based vector.